Irene Ghobrial, MD
Enriched profileSenior Vice President for Experimental Medicine; Director, Center for Early Detection and Interception of Blood Cancers; Co-Leader, Lymphoma/Myeloma Cancer Center Program · Dana-Farber Cancer Institute
Irene Ghobrial is Senior Vice President for Experimental Medicine; Director, Center for Early Detection and Interception of Blood Cancers; Co-Leader, Lymphoma/Myeloma Cancer Center Program at Dana-Farber Cancer Institute. OpenAlex indexes 1,125 publications with 46,685 citations (h-index 101); ClinicalTrials.gov lists 16 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Medical Oncology profiles in the findmyKOL directory.
Data verified 25 Aug 2026
Overview
Updated 14 Oct 2026
Irene Ghobrial, MD, is Senior Vice President for Experimental Medicine at Dana-Farber Cancer Institute. The public record shows 1,125 publications with 46,685 citations (h-index 101), centered on Multiple Myeloma Research and Treatments, Chronic Lymphocytic Leukemia Research, Protein Degradation and Inhibitors. It also documents an investigator role on 16 registered clinical trials, industry payments reported by 21 companies, 12 NIH-funded awards (2007–2026).
- Most recent indexed publication: 2026 · Blood cancer discovery
- Top research focus: Multiple Myeloma Research and Treatments
- 16 registered trials on ClinicalTrials.gov
- Open Payments reporting from 21 companies
Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 58 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 365.
Clinical & industry
trials, payments and federal fundingPublic positions
sourced statements on record- Presented on "Unmet Need" at the FDA Oncologic Drugs Advisory Committee (ODAC) meeting
March 15, 2024, regarding CARVYKTI (ciltacabtagene autoleucel) for relapsed/refractory multiple myeloma
2024provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →targetedonc.com ↗
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 14 Oct 2026
Listed as an investigator on 16 registered studies on ClinicalTrials.gov. The most recent:
- CAR- PRISM (PRecision Intervention Smoldering Myeloma)
Sponsor: Dana-Farber Cancer Institute
- Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)
Sponsor: Dana-Farber Cancer Institute
- Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma
Sponsor: Dana-Farber Cancer Institute
Industry payments
Updated 14 Oct 2026
21 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Regeneron Pharmaceuticals, Inc.Program year202511 payments$29,209openpaymentsdata.cms.gov ↗
- Janssen Global Services, LLCProgram year20251 payment
- SANOFI-AVENTIS U.S. LLCProgram year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
100%Thalidomide Analog100%Revlimid100%Part D≥14 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 14 Oct 2026
12 NIH research awards on record, funded 2007–2026 per NIH RePORTER. The latest:
- Molecular Prediction of Myeloma Initiation Molecular Prediction of Myeloma Initiation
Dana-Farber Cancer Inst
FY2026$1,040,400R35CA263817 - Defining immune determinants oftransformation in MGUS/SMM
Dana-Farber Cancer Inst
FY2026$959,573P01CA306849
Congress activity
Updated 14 Oct 2026
151 congress contributions (2004–2026) across AACR, ASCO, ASH per OpenAlex. The most recent:
- Abstract 2015: Single-cell atlas of tumor and immune cells in disease progression from MGUS to MM
AACR Annual Meeting
AACR2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 14 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- New Insights into the Role of Clonotypic B Cells in Plasma-cell Neoplasia.
Blood cancer discovery
Comment2026 - A Longitudinal Comprehensive Biospecimen and Clinical Data Repository for Cancer Early Detection: The InAdvance Study.
Cancer epidemiology, biomarkers & prevention
Article2026 - Pharmacological targeting of IRF4 as a therapeutic strategy for multiple myeloma.
Nature chemical biology
Article2026
Most-cited works
by citation count (OpenAlex)- 01Biological properties of extracellular vesicles and their physiological functionsArticle6,013 citations2015
- 02BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-MycArticle2,870 citations2011
- 03
- 04
- 05Targeting Apoptosis Pathways in Cancer TherapyArticle1,336 citations2005
Network
Updated 14 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 14 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- LinkedIn
linkedin.com/in/ireneghobrial
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - ResearchGate
researchgate.net/profile/Irene-Ghobrial
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗ - X / Twitter
x.com/ireneghobrial
Mentions by others
where others cite or feature them- LinkedIn
linkedin.com/posts/dana-farber-cancer-institute_congratulations-to-irene-ghobrial-md-dr-activity-7247353405940142083-pGVn
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - X / Twitter
x.com/labghobrial
- YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗ - YouTube
youtube.com/watch
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗ - YouTube
youtube.com/watch
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗ - YouTube
youtube.com/watch
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗ - Ascopost.com
Editorial board member, The ASCO Post
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ascopost.com ↗ - Ashpublications.org
Editorial board member, The Hematologist (ASH Publications)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ashpublications.org ↗ - LinkedIn
LinkedIn profile
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 14 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →dana-farber.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →dana-farber.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- Residency in Internal Medicine
Wayne State University
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →labs.dana-farber.org ↗ - Hematology/Oncology Fellowship
Mayo Clinic College of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →labs.dana-farber.org ↗
Editorial & leadership roles
journal and society appointments- Professor of Medicine
Harvard Medical School
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- Director
Clinical Investigator Research Program
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →labs.dana-farber.org ↗ - Director of Translational Research
Department of Multiple Myeloma
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →labs.dana-farber.org ↗ - Director
Center for Prevention of Progression Diseases (CPOP)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →labs.dana-farber.org ↗ - Director
Ghobrial Lab (Precursor Hematological Malignancies)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ghobriallab.dana-farber.org ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →en.wikipedia.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →en.wikipedia.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →the-asci.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →en.wikipedia.org ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
Media & interviews
press, podcasts and appearances- Hematologic Oncology Update podcast (iHeartRadio)
interview with Neil Love MD, Multiple Myeloma Update 1
2019verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →iheart.com ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →healthtree.org ↗
- The Patient Story
video interview on MGUS, smoldering, and active myeloma treatment/research
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →thepatientstory.com ↗ - HealthTree/Myeloma Crowd Radio
interview on the PROMISE study (myeloma screening)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →enroll.promisestudy.org ↗ - OncLive video interview
Key Objectives of the PROMISE Study in Multiple Myeloma
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗ - YouTube
COVID-19 Treatment Decision interview
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Kenneth Anderson, MD
Dana-Farber Cancer Institute
Paul Richardson, MD
Dana-Farber Cancer Institute
Toni Choueiri, MD
Dana-Farber Cancer Institute
Pasi Janne, MD, PhD
Dana-Farber Cancer Institute
Kenneth Anderson, MD
Dana-Farber Cancer Institute
Paul Richardson, MD
Dana-Farber Cancer Institute
S Rajkumar, MD
Mayo Clinic
Meletios Dimopoulos, MD
National and Kapodistrian University of Athens